Imaging the Folate Receptor on Cancer Cells with Tc-99m-Etarfolatide: Properties, Clinical Use, and Future Potential of Folate Receptor Imaging

Alan H. Maurer*, Philip Elsinga, Stefano Fanti, [No Value] Binh Nguyen, Wim J. G. Oyen, Wolfgang A. Weber

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

43 Citations (Scopus)

Abstract

Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. Tc-99m-etarfolatide, a Tc-99m-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.

Original languageEnglish
Pages (from-to)701-704
Number of pages4
JournalJournal of Nuclear Medicine
Volume55
Issue number5
DOIs
Publication statusPublished - May-2014

Keywords

  • folate receptor
  • imaging
  • Tc-99m-etarfolatide
  • SPECT
  • SPECT/CT
  • OVARIAN-CARCINOMA PATIENTS
  • PRECLINICAL EVALUATION
  • ACTIVATED MACROPHAGES
  • POSITIVE TUMORS
  • RHEUMATOID-ARTHRITIS
  • MONOCLONAL-ANTIBODY
  • PET RADIOTRACER
  • ALPHA
  • ACID
  • TC-99M-EC20

Cite this